Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).

Saved in:
Bibliographic Details
Title: Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
Authors: Malfona F; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Testi AM; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Moleti ML; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Petrucci L; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Leccisotti L; Nuclear Medicine Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome., Martelli M; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Di Rocco A; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Feb; Vol. 63 (2), pp. 483-486. Date of Electronic Publication: 2021 Oct 06.
Publication Type: Letter
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1029-2403
DOI:10.1080/10428194.2021.1978091